StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.97 | $1.94 | -1.52% | 0.1M |
| 05-12 | $1.92 | $1.92 | +0.00% | 0.1M |
| 05-13 | $1.90 | $1.84 | -3.16% | 0.1M |
| 05-14 | $1.91 | $2.09 | +9.42% | 0.3M |
| 05-15 | $2.00 | $1.83 | -8.50% | 0.3M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2018 2018-09-30 | Q2 2018 2018-06-30 | Q3 2017 2017-09-30 | Q2 2017 2017-06-30 |
|---|---|---|---|---|
Revenue | $203.00K | $148.00K | $204.00K | $147.00K |
Operating Income | $-17.18M | $-9.37M | $-41.92M | $-32.52M |
Net Income | $-16.64M | $-9.11M | $-42.45M | $-33.08M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $49.23M | $55.53M | $82.03M | $93.89M |
Total Liabilities | $4.32M | $5.32M | $9.74M | $12.74M |
Cash & Equivalents | $31.92M | $24.60M | $24.77M | $22.94M |
Free Cash Flow OCF − CapEx | $-14.44M | $-9.71M | $-37.69M | $-27.38M |
Shares Outstanding | 35.83M | 35.79M | 35.71M | 35.69M |
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.